Insight into cannabis use disorder in people with psychotic disorders
Edward Chesney, Millie Lloyd, Sébastien Brodeur, Arsime Demjaha, Lisa Conlan, Ikram Slimani, Ayşe Doğa Lamper, Ananya Sarma, Will Lawn, Dominic Oliver, Tom P. Freeman, R Murray, Marta Di Forti, Amir Englund, John Strang, Philip Mcguire
BJPsych Open August 25, 2026 DOI: 10.1192/bjo.2026.12064 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional study Peer reviewed |
|---|---|
| Sample size | 62 |
| Population | Adults with a psychotic disorder and comorbid cannabis use disorder |
| Measures | Substance Use Awareness and Insight Scale, DSM-5 criteria |
| Topics | Cannabis |
| Key findings | Insight into cannabis use disorder was limited in this sample, with a mean Substance Use Awareness and Insight Scale total score of 4.8 (s.d. 2.1) and lowest subdomain scores for awareness of need for treatment (3.5) and general illness awareness (3.7). Most participants (58%) believed cannabis improved their mental health, yet 53% wanted to reduce or stop using it. The authors suggest impaired insight and positive beliefs about cannabis may contribute to persistent use. |
Abstract
Background: Cannabis use is common in people with psychosis and is associated with poor outcomes.
Aims: To assess insight into cannabis use disorder, perceptions about how cannabis use influences mental health and the desire to change cannabis use among people with psychotic disorders.
Method: Adults with a psychotic disorder and comorbid cannabis use disorder were asked about the impact of cannabis use on their illness and their desire to change cannabis use. Cannabis use disorder was determined using DSM-5 criteria. Participants completed the Substance Use Awareness and Insight Scale.
Results: Sixty-two participants (mean age: 42 years; 95% male; 65% Black ethnicity; 85% severe DSM-5 cannabis use disorder) completed the study. The mean total Substance Use Awareness and Insight Scale score was 4.8 (s.d.: 2.1), with subdomain scores of 3.7 (s.d.: 2.8) for general illness awareness, 6.2 (s.d.: 2.8) for symptom attribution, 3.5 (s.d.: 2.9) for awareness of need for treatment and 5.6 (s.d.: 3.8) for awareness of negative consequences. Fifty-eight per cent said that cannabis use made their mental health 'better', whereas only 15% said it made it 'worse'; 27% reported that cannabis made their psychotic symptoms 'better', and 21% said it made them 'worse'. Nevertheless, more than half the sample (53%) said they wanted to reduce or stop using cannabis.
Conclusions: Many people with psychotic disorders have impaired insight into cannabis use disorder or believe that cannabis improves their mental health; these factors may contribute to persistent use in this population. Interventions that improve insight may help to address ambivalence and support those already wishing to reduce use.
Comparable studies
Other cross-sectional and survey studies on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Cannabis use before age 15 and subsequent executive functioning 104 chronic cannabis users (49 early-onset before age 15, 55 late-onset after age 15)... | 2011 | Observational cross-sectional study | n = 148 |
| Patterns of simultaneous polysubstance use in drug using university students Drug-using university students | 2006 | Cross-sectional survey | n = 149 |
| Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey Online survey respondents | 2020 | Cross-sectional survey | |
| User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study Users of hallucinogenic drugs who completed a web-based questionnaire | 2010 | Cross-sectional survey | n = 600 |
| Illicit Use of LSD or Psilocybin, but not MDMA or Nonpsychedelic Drugs, is Associated with Mystical Experiences in a Dose-Dependent Manner Adults recruited from the MAPS website and newsletter, most reporting use of various... | 2012 | Cross-sectional survey | n = 337 |
Citations in the library
Cites 9
- Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis The Lancet Psychiatry July 10, 2017
- Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study Psychological Medicine March 18, 2020
- Patient’s Perceptions of the Cannabis-psychosis Link - A Systematic Review Current Pharmaceutical Design September 12, 2012
- Psychosis associated with cannabis withdrawal: systematic review and case series The British Journal of Psychiatry December 3, 2024
- Assessing Cannabis Use in People with Psychosis Cannabis and Cannabinoid Research February 1, 2024
and 4 more in the library